With our increased understanding of the molecular mechanisms of haematological disorders, it has become possible to target therapy precisely to the underlying defect. Targeted therapy can increase safety and potency, while causing fewer side effects than standard treatment. "Smart" drugs and gene therapy have recently shown great promise in a wide range of malignant haematological and coagulation disorders.
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
- 1 Haematology Department, Royal Perth Hospital, University of Western Australia, Perth, WA.
- 2 Haematology Department, Alfred Hospital, Melbourne, VIC.
- 3 Haematology Department, Mater Hospital, Brisbane, QLD.
Correspondence: ross.baker@health.wa.gov.au
- 1. Goldman JM, Melo JV. Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344: 1084-1086.
- 2. White GC. Gene therapy in haemophilia: clinical trials update. Thromb Haemost 2001; 86: 172-177.
- 3. Schnipper LE, Strom TB. A magic bullet for cancer — how near and how far? N Engl J Med 2001; 345: 283-284.
- 4. Rosenberg RD. Redesigning heparin. N Engl J Med 2001; 344: 673-675.
- 5. Hirsh J. New anticoagulants. Am Heart J 2001; 142 (2 Suppl): S3-S8.
Online responses are no longer available. Please refer to our instructions for authors page for more information.